logo-loader
Genedrive PLC

Genedrive PLC optimistic on the long-term opportunity for its HCV test

Genedrive PLC (LON:GDR) CEO David Budd tells Proactive London's Andrew Scott he remains confident the World Health Organisation will pre-qualify its HCV ID hepatitis C test in the near term despite some delays to the clinical trial.

He adds that the development of an antibiotic-induced hearing loss test with the NHS is ahead of schedule, with in-hospital trials expected to begin in the autumn after CE marking requirements.

Quick facts: Genedrive PLC

Price: 19.5 GBX

Market: AIM
Market Cap: £6.63 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Bezant Resources to sell 80% interest in Mankayan copper...

Headlines from the Proactive UK newsroom. Bezant (LON:BZT) has entered into a conditional deal with a private company based in Singapore to sell an 80% interest in the Mankayan copper-gold project in the Philippines. The deal constitutes a reverse takeover under the Singapore stock exchange...

2 weeks, 1 day ago

RNS

Holding(s) in Company

8 hours, 52 minutes ago

Holding(s) in Company

8 hours, 53 minutes ago

Final Results

2 weeks, 5 days ago

Notice of Results

on 9/9/19

Trading Update

on 9/7/19

2 min read